trending Market Intelligence /marketintelligence/en/news-insights/trending/xdslx8tdnjwjefphmd64ma2 content esgSubNav
In This List

Former Kite Pharma exec joins Autolus' board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Former Kite Pharma exec joins Autolus' board

Autolus Ltd. added Cynthia Butitta to its board.

Butitta previously worked as the COO of Kite Pharma Inc. until its $11.9 billion acquisition by Gilead Sciences Inc. She also served as Kite Pharma's CFO from January 2014 to May 2016.

London-based Autolus is a privately held biotechnology company that develops T cell immunotherapies to treat cancer. It recently filed for a potential U.S. IPO